98%
921
2 minutes
20
Background: Primary hypothyroidism is characterized by a loss of thyroxine feedback inhibition and an increase in thyrotropin-releasing hormone (TRH) levels, resulting in reactive pituitary hyperplasia. However, it is important to note that pituitary hyperplasia due to primary hypothyroidism (PHPH) is rare, particularly when symptoms of pituitary mass compression are present.
Case Summary: A patient with menstrual irregularities and hyperprolactinemia exhibited pituitary enlargement on magnetic resonance imaging (MRI). Initial treatment with bromocriptine mesylate failed, leading to surgical resection. Preoperative evaluation revealed severe hypothyroidism. Postoperatively, discontinuation of medication resulted in elevated thyroid-stimulating hormone (TSH) levels. Reticulin staining confirmed TSH hyperplasia, likely due to long-standing, untreated hypothyroidism since childhood. Postoperative thyroid hormone therapy restored normal thyroid and pituitary functions.
Conclusion: This case underscores the importance of recognizing long-standing hypothyroidism as a potential cause of pituitary hyperplasia. Accurate diagnosis is essential to avoid unnecessary surgical or pharmacological interventions.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12394464 | PMC |
http://dx.doi.org/10.3389/fmed.2025.1601190 | DOI Listing |
Cureus
August 2025
Gynecologic Oncology, University of Georgia, Tbilisi, GEO.
This case report elucidates the diagnostic trajectory of a female newborn, presenting with apparent clitoromegaly, ultimately diagnosed with congenital adrenal hyperplasia (CAH). The patient was born in a prominent obstetrics and gynecology center in Tbilisi, Georgia, where the anomaly was promptly identified following a physiologically normal pregnancy and labor. Despite the relative infrequency of such cases in our center, particularly among term infants, the handling of this case was swift and successful.
View Article and Find Full Text PDFFront Med (Lausanne)
August 2025
Department of Cardiothoracic Surgery, Cixi People Hospital Medical Health Group (Cixi People Hospital), Ningbo, China.
Background: Primary hypothyroidism is characterized by a loss of thyroxine feedback inhibition and an increase in thyrotropin-releasing hormone (TRH) levels, resulting in reactive pituitary hyperplasia. However, it is important to note that pituitary hyperplasia due to primary hypothyroidism (PHPH) is rare, particularly when symptoms of pituitary mass compression are present.
Case Summary: A patient with menstrual irregularities and hyperprolactinemia exhibited pituitary enlargement on magnetic resonance imaging (MRI).
Vet Sci
August 2025
Department of Clinical Science and Services, Royal Veterinary College, Hawkshead Lane, North Mymms, Hertfordshire AL9 7TA, UK.
Pituitary pars intermedia dysfunction (PPID) is a common, slowly progressive, neurodegenerative disorder of the older horse. Oxidative damage to the hypothalamic periventricular neurons results in loss of dopaminergic inhibition of the pars intermedia region of the pituitary gland. Consequently, there is increased production of the pro-opiomelanocortin (POMC)-derived hormones normally produced by this region, as well as initial melanocyte hypertrophy and hyperplasia, followed by adenomatous change.
View Article and Find Full Text PDFJ Transl Med
August 2025
Department of Neurosurgery, Center of Pituitary Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, People's Republic of China.
Background: Cushing's disease (CD) is a clinical syndrome caused by excessive secretion of adrenocorticotropic hormone (ACTH) from a pituitary corticotroph adenoma, resulting in adrenal cortical hyperplasia and overproduction of cortisol. The T-box transcription factor (TPIT) is crucial for regulating ACTH secretion in pituitary corticotroph adenomas. This study aims to explore the ubiquitin-mediated degradation of TPIT and identify potential pharmaceutical agents for treating CD.
View Article and Find Full Text PDFEnviron Toxicol Chem
August 2025
Experimental Pathology Labs, Oak Grove, VA, USA.
The Amphibian Metamorphosis Assay (AMA) was established as a standardized guideline test with the primary purpose of evaluating test materials for potential endocrine activity in the Hypothalamus-Pituitary-Thyroid axis of developing African clawed frogs (Xenopus laevis). The Extended Amphibian Metamorphosis Assay (EAMA) is similar to the AMA with a key difference in that the EAMA terminates at a fixed developmental stage (ie Nieuwkoop and Faber (NF) stage 62) rather than at a fixed exposure time of the AMA (ie, 21-days). This paper summarizes the control data at NF stage 62 for a total of seventeen EAMAs conducted at two different laboratories.
View Article and Find Full Text PDF